How to Get Jardiance in California

Why California Patients Seek Jardiance Online

Jardiance has become one of the most prescribed cardiometabolic drugs in the United States. Demand surged after EMPA-REG OUTCOME (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease who were randomized to empagliflozin versus placebo [1]. That magnitude of benefit, published in the New England Journal of Medicine in 2015, reshaped guideline writing across cardiology and endocrinology [1].

California has more than 3.3 million adults living with diagnosed diabetes according to CDC surveillance data [2]. Many of them are under-treated or have difficulty reaching specialists, particularly in inland and rural counties. Telehealth removes that barrier entirely: a licensed California clinician can evaluate a patient via video, order labs at a local draw site, and send an electronic prescription to any in-state pharmacy, all without a single in-person visit for a non-controlled medication like empagliflozin [3].

The drug is not classified as a controlled substance under federal or California law, which means it is not subject to the DEA's telehealth prescribing restrictions that tightened after 2023 [4]. That distinction matters. A telehealth clinician can legally prescribe Jardiance to a California patient on the first video visit, provided the clinical evaluation is sufficient to support the indication.

Who Can Legally Prescribe Jardiance in California

Any fully licensed MD, DO, nurse practitioner (NP) with a California Board of Registered Nursing furnishing number, or physician assistant (PA) working under a supervising physician agreement may prescribe empagliflozin in California [5]. The California Business and Professions Code sections 2836.1 and 3502.1 govern NP and PA prescriptive authority, respectively [5].

Telehealth prescribing follows the same rules. The California Telehealth Advancement Act (Business and Professions Code section 2290.5) explicitly allows clinicians to establish a patient-provider relationship via synchronous video and issue prescriptions without a prior in-person encounter, as long as the standard of care is met [3]. Audio-only visits may also satisfy this requirement when video is not available to the patient.

In practice, most telehealth platforms serving California patients use board-certified internal medicine physicians, endocrinologists, or nurse practitioners with cardiology training to handle empagliflozin requests. The American Diabetes Association's 2024 Standards of Care list SGLT2 inhibitors as a first-line add-on to metformin for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of HbA1c [6]. That guideline recommendation means clinicians have clear algorithmic support for prescribing.

Required Labs Before a California Clinician Will Prescribe

Labs are required. No competent clinician will prescribe empagliflozin without a current estimated glomerular filtration rate (eGFR) and serum creatinine, because the drug's renal handling and efficacy thresholds are eGFR-dependent [7].

The FDA label for Jardiance specifies that empagliflozin is not recommended when eGFR is persistently below 20 mL/min/1.73 m² [8]. For patients with CKD, the EMPA-KIDNEY trial (N=6,609) showed that empagliflozin 10 mg once daily reduced the composite of kidney disease progression or cardiovascular death by 28% relative to placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001), with benefit observed even at eGFR as low as 20 mL/min/1.73 m² [9].

A standard pre-prescription panel in California typically includes:

• eGFR and serum creatinine (required before prescribing; repeated 4 weeks after dose changes)
• HbA1c (for the diabetes indication; establishes baseline and supports prior authorization)
• Urinalysis with microscopy (to screen for active urinary tract infection or heavy proteinuria)
• Basic metabolic panel (potassium, bicarbonate, and glucose to screen for diabetic ketoacidosis risk factors)
• Blood pressure (empagliflozin has a modest blood pressure-lowering effect of 3 to 5 mmHg systolic in controlled trials [10])

Most California telehealth providers use Quest Diagnostics or LabCorp for draws; results typically return within 24 to 48 hours. A clinician can review them asynchronously and send the prescription electronically the same day results arrive.

How the Telehealth Appointment Works in California

The process is shorter than most patients expect. A California telehealth visit for Jardiance typically runs 15 to 20 minutes when the patient uploads recent labs in advance.

During the visit, the clinician will confirm the indication (type 2 diabetes, heart failure, or CKD), review current medications for interactions (specifically loop diuretics and insulin, which carry hypoglycemia and volume-depletion risk when combined with SGLT2 inhibitors [8]), and assess for contraindications including recurrent genitourinary infections and a history of diabetic ketoacidosis. Patients on insulin may need a pre-specified dose reduction plan before starting empagliflozin, since combined use increases euglycemic DKA risk [8].

After the visit, the clinician sends an electronic prescription (eRx) to the patient's chosen pharmacy. California pharmacies are required to accept eRx for non-controlled medications under Health and Safety Code section 11164. The patient receives a text or email confirmation, and the drug ships or is available for same-day pickup.

Jardiance Dosing and Titration

Empagliflozin comes in two strengths: 10 mg and 25 mg, both taken once daily in the morning with or without food [8]. The starting dose across all indications is 10 mg. For patients using Jardiance primarily for glycemic control in type 2 diabetes, clinicians may titrate to 25 mg after 4 weeks if the 10 mg dose is tolerated and additional HbA1c reduction is needed [8].

For heart failure and CKD indications, the 10 mg dose was the dose used in the key trials. EMPEROR-Reduced (N=3,730) randomized patients with heart failure and reduced ejection fraction (HFrEF, EF <40%) to empagliflozin 10 mg or placebo and found a 25% relative risk reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [11]. There is no established additional benefit from the 25 mg dose in heart failure, and current guidelines do not recommend routine titration for that indication [12].

EMPEROR-Preserved (N=5,988) extended the benefit to heart failure with preserved ejection fraction (HFpEF, EF >40%), where empagliflozin 10 mg reduced cardiovascular death or hospitalization for heart failure by 21% relative to placebo (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [13]. This was the first large randomized trial to show a statistically significant outcome benefit in HFpEF, a population with very few proven therapies.

Insurance Coverage and Prior Authorization in California

Medi-Cal covers empagliflozin for type 2 diabetes, heart failure, and CKD, but requires prior authorization (PA) for all three indications [14]. Commercial insurers in California follow similar rules. The prior authorization documentation package typically includes:

• Current HbA1c (diabetes indication) or echocardiogram report confirming EF (heart failure indication) or two consecutive eGFR measurements at least 90 days apart (CKD indication)
• Evidence of first-line therapy failure or intolerance (usually metformin for T2DM, or ACE inhibitor/ARB for CKD and HF)
• The prescribing clinician's NPI number and attestation of medical necessity

The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven cardiovascular or renal benefit is recommended as part of the glucose-lowering regimen independent of HbA1c" [6]. Quoting this language directly in a PA letter significantly strengthens approval rates.

Turnaround for Medi-Cal PA decisions is 3 business days for standard requests and 72 hours for expedited requests under California's utilization management regulations [14]. Commercial insurer timelines vary, but most decisions arrive within 5 to 7 business days.

If PA is denied, the prescribing clinician can appeal at the peer-to-peer level. Data from EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY form the strongest possible clinical argument for medical necessity [1][9][11][13].

California Pharmacy Options for Filling Jardiance

Retail pharmacies. All major retail chains operating in California (CVS, Walgreens, Rite Aid successor locations, and regional independents) stock both the 10 mg and 25 mg tablets. A 30-day supply is available same-day at any location that has inventory. Call ahead if you are picking up the same day, since 25 mg tablets are stocked less consistently than 10 mg at smaller independents.

Mail-order and specialty pharmacies. For patients using mail-order benefits through their insurer, a 90-day supply typically ships within 3 to 5 business days after the eRx is processed and PA is confirmed. Cost for a 90-day supply without insurance ranges from approximately $580 to $640 at GoodRx-negotiated rates as of mid-2025; with insurance and a manufacturer coupon, out-of-pocket cost may be as low as $10 per month for eligible commercially insured patients using the Boehringer Ingelheim/Lilly savings card [8].

503A compounding pharmacies. California-licensed 503A pharmacies may compound empagliflozin for patients with documented medical necessity, such as a need for a different dose form or a filler allergy confirmed by an allergist. The California State Board of Pharmacy oversees 503A facilities and requires that each compounded preparation be dispensed pursuant to a valid patient-specific prescription [15]. Compounded empagliflozin is not FDA-approved and is not equivalent to brand-name Jardiance for regulatory purposes; clinicians should document the rationale clearly in the medical record.

Transferring a Jardiance Prescription to California

California accepts transferred prescriptions for non-controlled medications from any other U.S. state. A California pharmacist can contact the out-of-state pharmacy by phone or electronic transfer system to request the original prescription. Under California Business and Professions Code section 4063, a non-controlled prescription may be transferred once between pharmacies in different states [16].

If the original prescription had refills remaining, those refills transfer with it. If the prescription was written by an out-of-state clinician and has no refills remaining, the California patient will need a new prescription from a California-licensed clinician, which can be obtained via a telehealth visit without an in-person appointment [3].

Patients who relocate to California and need an immediate bridge supply should ask the receiving California pharmacist to perform a concurrent transfer call with the originating out-of-state pharmacy. Most chains can complete this within the same business day.

Side Effects California Patients Should Know Before Starting

Empagliflozin is generally well tolerated, but three adverse effects require patient education before the first dose:

Genitourinary infections. The SGLT2 mechanism increases urinary glucose, which raises infection risk. In EMPA-REG OUTCOME, genital mycotic infections occurred in 6.4% of women and 3.1% of men on empagliflozin versus 1.8% and 0.9% on placebo, respectively [1]. Patients with recurrent vulvovaginal candidiasis or balanitis should discuss this risk explicitly with their prescribing clinician before starting.

Volume depletion. Empagliflozin produces a modest osmotic diuresis. Patients already on loop diuretics or those with baseline low blood pressure may experience dizziness, particularly in the first 2 to 4 weeks [8]. Clinicians frequently reduce loop diuretic doses by 25 to 50% when starting an SGLT2 inhibitor in heart failure patients.

Euglycemic diabetic ketoacidosis. Rare but serious. DKA can occur even when blood glucose is below 250 mg/dL. Risk factors include very-low-carbohydrate diets, prolonged fasting, excessive alcohol use, and insulin dose reduction. The FDA issued a safety communication on this risk in 2015 [4]. Patients should be instructed to hold empagliflozin 3 days before elective surgery and to seek emergency evaluation if they develop nausea, vomiting, or abdominal pain.

Patients with a confirmed sulfa allergy do not have a cross-reactivity concern with empagliflozin, as the drug does not contain a sulfonamide moiety [8].

Monitoring After Starting Jardiance in California

After the first prescription, monitoring is straightforward. A repeat eGFR and serum creatinine at 4 weeks is standard practice to confirm the expected transient 3 to 5 mL/min/1.73 m² dip in eGFR that occurs with SGLT2 inhibitor initiation [7][9]. This dip is hemodynamic, not structural, and reverses on discontinuation. Clinicians who do not warn patients about it risk unnecessary alarm and early discontinuation.

HbA1c should be rechecked at 3 months for the diabetes indication to assess glycemic response. Blood pressure should be checked at the 4-week visit, especially in patients on antihypertensives, since empagliflozin reduces systolic blood pressure by 3 to 5 mmHg on average [10]. Dose adjustments for concomitant antihypertensives may be needed.

Annual urinalysis and urine albumin-to-creatinine ratio (UACR) monitoring is recommended for patients with CKD, per KDIGO 2024 guidelines, which classify SGLT2 inhibitors as a cornerstone of CKD therapy independent of diabetes status [7].

Cost-Reduction Programs Available to California Patients

The Boehringer Ingelheim/Lilly Jardiance Savings Card reduces out-of-pocket cost to $10 per 30-day supply for eligible commercially insured patients, with a maximum savings cap of $150 per fill [8]. The card is not valid for patients with federal insurance (Medicare, Medicaid, TRICARE), but Medi-Cal patients may qualify for the manufacturer's patient assistance program, which provides free drug to patients meeting income thresholds [8].

GoodRx and similar discount programs negotiate cash-pay prices at California retail pharmacies to approximately $580 to $610 for a 30-day supply of 25 mg tablets. The 10 mg strength is priced similarly. Generic empagliflozin is not yet available in the United States as of mid-2025, though Boehringer Ingelheim's patent exclusivity for the molecule is expected to face its first legal challenge by 2026.